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Previewsof SCFAs in the gut so as to drive the dif-
ferentiation of naive CD4+ T cells into Treg
cells and not into Th1 and Th17 cells. This
can be achieved with the use of appro-
priate types of dietary fiber that have the
ability to support the growth and prolifer-
ation of SCFA-producing gut microbes.
Prebiotics such as fructo-oligosaccha-
rides are known to increase the levels of
SCFAs in the gut. Probiotics containing
selective species of bacteria known to
produce SCFAs as themajor fermentation
products can also be used to achieve this
goal. Oral delivery of SCFAs might be
problematic because these fatty acids
are metabolized extensively in the upper
portions of the intestinal tract with only a
minor fraction of the original oral dose
entering the ileum and colon wheremajor-
ity of mucosal immune cells reside. But,
SCFAs can be chemically modified
(e.g., SCFAs esterified to starch) andthen administered orally, an approach
that is likely to result in delivery of appre-
ciable amounts of SCFAs to the distal
portions of the intestinal tract. The studies
by Haghikia and colleagues (2015) pro-
vide convincing evidence in support of
therapeutic potential of such approaches
for prevention and/or treatment of autoim-
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Predicting cancer patients’ response to therapy is essential for curing disease and improving quality of life.
Garraway and colleagues demonstrate that the frequency and number of neoantigens, non-synonymous
mutations, and adaptive immune genes, but not the assessment of individual recurrent neoantigens or mu-
tations, predicts patient responses to immunotherapy.The recent success of immunotherapies
targeting immune-checkpoint molecules
cytotoxic T lymphocyte-associated anti-
gen-4 (CTLA4), programmed cell death-
1 (PD-1), and programmed cell death li-
gands (PD-L1 and PDL-2) in the treatment
of cancer has emphasized the essential
role of the immune system in the eradica-
tion of tumors. Although these immuno-
therapies have had stunning results, the
percentage of patients who see a clinical
benefit is limited, and the factors that
determine whether a patient will have animproved clinical response are not well
understood. The ability to predict whether
a patient will respond or become resistant
to immunotherapy is essential for finding a
cure for cancer.
One approach to finding new cancer-
response biomarkers is identifying anti-
gens that are unique to tumors. An
example of these are neoantigens, which
are mutated peptides that arise in tumors
and thus are not present in the normal
genome (Schumacher and Schreiber,
2015). Identifying novel neoantigens hasrecently become more feasible with
whole-exome sequencing. Researchers
use RNA sequencing of tumors to identify
mutations in expressed genes. They can
then process these data in silico to iden-
tify biologically likely peptide-MHC com-
binations. It is hypothesized that more
immunogenic tumor types have higher
rates of somatic mutation and therefore
elevated numbers of neoantigens (Schu-
macher and Schreiber, 2015).
In a recent issue of Science, Van Allen
et al. describe extensive analysis of, October 20, 2015 ª2015 Elsevier Inc. 631
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Previewswhole-exome sequencing and transcrip-
tome data from tumor biopsies of 40 pa-
tients with metastatic melanoma before
and after CTLA-4-blocking immuno-
therapy (Van Allen et al., 2015). They
show that patients with a high number
and frequency of neoantigens and non-
synchronous mutations in their tumor are
more likely to respond to anti-CTLA-4
immunotherapy. However, when identi-
fying common neoantigens between pa-
tients that responded to therapy, the au-
thors found that no single antigen or
mutation correlated with clinical benefit.
Interestingly, when the authors examined
the expression of immune genes associ-
ated with cytolytic activity (perforin, gran-
zyme A) and checkpoint molecules
(CTLA-4, PD-L2), patients who had clin-
ical benefit from therapy had higher
expression of these genes in their tumors.
These findings support accumulating
data suggesting that it is not singular mu-
tations that predict patients’ clinical
outcome, but the presence of a high num-
ber of mutations and global T cell re-
sponses in the tumor microenvironment.
Similarly to the findings of Van Allen
et al., several studies have previously
demonstrated that the mutational load
and the frequency of neoantigens corre-
lates with the response to anti-CTLA-4
and anti-PD-1 and/or anti-PD-L1 immu-
notherapy in melanoma, lung, and MSI-
positive colorectal cancers (Koster et al.,
2015). Although there has been consider-
able research into single neoantigens that
could serve as targets for immunotherapy
or as biomarkers for patient survival,
relapse, or response to therapy, the
biology of peptide presentation is exces-
sively complex and has yielded few
good candidates. This is partially due to
the fact that antigenic peptide processing
is a complicated process that involves a
multitude of human lymphocyte antigens
(HLAs) (Schumacher and Schreiber,
2015).
Multiple types of cancer antigens,
including (1) neoantigens, such as muta-
tions and viral antigens, (2) self-proteins
that are either overexpressed or usually
not expressed in most of the adult body
(e.g., cancer testis antigens), and (3) tis-
sue-specific gene products, which would
be of interest if the cancer affects a tissue
or cell type not essential for the life of the
patient (e.g., B cells, melanocytes or pros-
tate), have been characterized. Further-632 Immunity 43, October 20, 2015 ª2015 Elmore, antigenic peptides do not simply
correspond to fragments of conventional
proteins but rather result from aberrant
transcription, incomplete splicing, transla-
tion of alternative or cryptic open-reading
frames, or post-translational modifica-
tions. Proteasome peptide splicing repre-
sents another mechanism that increases
the diversity of antigenic peptides pre-
sented to T cells (Vigneron et al., 2004).
Cancer-associated aberrant-protein O-
glycosylation can modify antigen pro-
cessing and immune response (Madsen
et al., 2012). MHC class I–associated
phosphopeptides are the targets of mem-
ory-like immunity, and results point to a
role for phosphopeptide-specific immu-
nity as a component of tumor recognition
and control (Cobbold et al., 2013). Thus,
beyond exome sequencing and point mu-
tations, various tumor alterations might
lead to tumor-specific immunity, and mul-
tiple immune biomarkers are likely candi-
dates for predicting a patient’s response
to immune-checkpoint therapies.
Interestingly, when focusing on clusters
ofmutations that predict patient outcome,
there is growing evidence that immune
gene expression is an attractive candi-
date (Bindea et al., 2013). Similar to the
findings of Van Allen et al., studies in colo-
rectal cancer have shown that there are
many common germline mutations
among tumors but that neoantigen muta-
tions are distinct between patients (Ange-
lova et al., 2015). However, in compari-
sons of highly mutated tumors to less
mutated tumors, tumors with more muta-
tions had an immune signature consisting
of depleted immunosuppressive cells
and upregulated immune-inhibitory mole-
cules. Conversely, less mutated tumors
had amplified immunosuppressive cells,
downregulation of HLA molecules, and
reduced expression of immune-inhibitory
molecules. Additionally, the adaptive im-
mune response is highly accurate at pre-
dicting patient outcome (Bindea et al.,
2013). This is particularly true for genomic
alterations in chemokines and cytokines
related to T cell trafficking and homeosta-
sis. The adaptive immune response is
shaped by CD8+ andCD4+ T cells, B cells,
and follicular helper T cells (Tfh) that help
organize lymphoid structures. Inter-
leukin-21 (IL-21) and IL-15 are part of the
gamma-chain cytokine family and are
crucial for survival and proliferation of
Tfh, cytotoxic, and memory T cells.sevier Inc.Consequently, both IL-21 and IL-15 are
being used in clinical trials as immuno-
therapies for cancer.
The predictive capability of immuno-
genic mutations in the tumor highlights
the importance of studying the tumor
microenvironment as a whole. The im-
mune contexture of the tumor microenvi-
ronment defines the immune parameters
associated with survival of the patients
(Galon et al., 2013; Galon et al., 2006). It
has been extensively reported that pa-
tients with cytotoxic T cells in the primary
tumor have improved survival regardless
of the type of therapy administered (Galon
et al., 2013). Moreover, if the pre-existing
adaptive immune response within the tu-
mor microenvironment is further defined
by location, either at the tumor center or
the invasive margin, by a measure termed
Immunoscore, this statistically predicts
patient outcome better than the current
TNM staging strategy (Galon et al., 2013).
The presence of T cells in the tumor as a
predictor of clinical benefit to immuno-
therapy has also been shown in response
to anti-PD1 immunotherapy (Koster et al.,
2015). The density of CD8 T cells, as as-
sessed by immunohistochemistry, in the
tumor center and especially at the inva-
sive margin were directly correlated with
response to PD-1-blocking immuno-
therapy. Multiple studies have shown
that PD-L1 co-localizes with CD8 infil-
trates in tumors. Thus, infiltrating T cells
induced adaptive immune resistance
associated with increased expression of
PD-L1. Similar to the findings of Van Allen
et al., both CD8 and PD-L1 were also
significantly more highly expressed in tu-
mors of patients that responded to anti-
PD-1 therapy than in those of patients
that did not respond.
Prognostic markers are useful for as-
sessing the risk for an individual patient
and providing helpful insights into cancer
biology. However, they do not assist in
treatment selection according to the likeli-
hood of therapeutic effectiveness, a role
that pertains to predictive biomarkers.
Determining the mechanisms (mecha-
nistic signatures) associated with treat-
ment success (or failure) at the time
when tumor rejection is occurring is crit-
ical to understanding immune-mediated
tumor regression (Galon et al., 2013). Pa-
rameters associated with the immune
contexture have been associated with
predictive signatures and include T helper
Figure 1. Predictive and Mechanistic Signatures for Cancer Immunotherapy
Predictive biomarkers (blue and green) that are present in the tumor microenvironment prior to treatment
and that infer clinical benefit to immunotherapy include large numbers of immunogenic mutations, anti-
tumor T cells (CD3), cytotoxic T cells (granzymes-GZM, perforin-PRF, and granulysin-GNLY), chemo-
kines, TCR repertoire diversity, anti-tumor antibodies, decreased circulating myeloid-derived suppressor
cells (cMDSCs), and soluble CD25 (sCD25) in the serum. Highly mutated tumors can contain a wide variety
of immunogenic peptides that help elicit the anti-tumor immune response. Many predictive markers also
serve as mechanistic biomarkers (green), which are increased (or decreased) after treatment with
immunotherapy and correlate with clinical benefit. Additionally, there are unique mechanistic signatures
(yellow) that one can measure after immunotherapy to determine clinical benefit. These include increased
absolute leukocyte count (ALC), decreased circulating ratio of neutrophils to lymphocytes (cNLR), and
decreased lactate dehydrogenase (LDH) in the serum. An asterisk marks previously described immuno-
genic peptides, including overexpressed self-proteins (e.g., Tyrosinase), cancer testis antigens (e.g., NY-
ESO-1), tissue-specific gene products (e.g., MART-1), phosphopeptides, and peptides resulting from
aberrant transcription, incomplete splicing, translation of alternative or cryptic open-reading frames, post-
translational modifications, proteasome peptide splicing, and aberrant protein O-glycosylation. A number
sign marks biomarkers described by Van Allen et al.
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Previewstype 1 (Th1) factors, CD8 T cells and prolif-
erating T cells, immune effector or cyto-
toxic factors, chemokines, and adhesion
molecules (Galon et al., 2013; Galon
et al., 2006). Prognostic, predictive, and
mechanistic immune signatures are
largely overlapping. The similarity be-
tween mechanistic signatures associated
with tumor rejection amongdistinct immu-
notherapeutic approaches (including anti-CTLA4) provides evidence that tissue
destruction triggered by different im-
mune-therapy approaches converges,
when effective, into a common mecha-
nism (Galon et al., 2013). (Figure 1).
Overall, the studies evaluating immune-
checkpoint blockade molecules (i.e., anti-
CTLA4 and anti-PD1 and/or anti-PD-L1
mAbs) have provided two important hy-
potheses. The first is that in metastaticImmunity 43cancers, the immune system is not an
inert system but rather is an actively sup-
pressed one. The second hypothesis is
that tumors responsive to treatment
display an inflammatory status accompa-
nied by the concomitant counter-activa-
tion of immune-suppressivemechanisms,
probably reflecting ongoing immune-
escape processes. Thus, pre-exiting
adaptive immunity is essential for im-
mune-checkpoint immunotherapies.
Mutational load and neoantigen fre-
quency appear to be among the tumor
molecular alterations leading to stronger
pre-exiting adaptive immunity and to the
expression of cytolytic markers that are
robust determinants of response to im-
mune-checkpoint inhibitors.REFERENCES
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